慢性粒细胞白血病
髓性白血病
生物
髓样
医学
免疫学
作者
Yun Wang,Zhen Liang,Robert Peter Gale,Hai Liao,Jun Ma,Tiejun Gong,Yingqi Shao,Yang Liang
标识
DOI:10.1016/j.blre.2024.101196
摘要
Chronic myeloid leukaemia (CML) is caused by BCR::ABL1. Tyrosine kinase-inhibitors (TKIs) are the initial therapy. Several organizations have reported milestones to evaluate response to initial TKI-therapy and suggest when a change of TKI should be considered. Achieving treatment-free remission (TFR) is increasingly recognized as the optimal therapy goal. Which TKI is the best initial therapy for which persons and what depth and duration of molecular remission is needed to achieve TFR are controversial. In this review we discuss these issues and suggest future research directions.
科研通智能强力驱动
Strongly Powered by AbleSci AI